Mineralys Therapeutics, Inc. (MLYS) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Radnor, PA, 美国. 现任CEO为 Jon Congleton.
MLYS 拥有 IPO日期为 2023-02-10, 51 名全职员工, 在 NASDAQ Global Select, 市值为 $1.81B.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
